Client Successes

Amgen Launches New Neulasta® (Pegfilgrastim) Wearable Delivery Kit

In 2015, Amgen announced that the Neulasta® (pegfilgrastim) OnPro™ Kit is now available in the United States (U.S.). The Neulasta® OnPro™ Kit includes a specially designed single-use prefilled syringe co-packaged with a new On-Body Injector. With the Neulasta® OnPro™ Kit, the healthcare provider (HCP) initiates administration of Neulasta® with the On-Body Injector on the same day as cytotoxic chemotherapy. Administration is delayed however, and this results in the automatic delivery of the patient's full dose of Neulasta® the day following chemotherapy administration. This advantageously eliminates the need for the patient to return to the HCP to receive the Neulasta® injection, which can be physically and emotionally challenging a mere day following cytotoxic chemotherapy treatment.

Marshall, Gerstein & Borun LLP worked closely with Amgen to navigate a sophisticated and complex field of prior art to build a robust international patent portfolio directed to the novel On-Body Injector included within the Neulasta® OnPro™ Kit.

Infections send 200,000–300,000 cancer patients to the hospital per year. The Neulasta® OnPro™ Kit makes delivery of infection-fighting drugs one less worry for those fighting the disease.

Easing the Use of Patient Care at Home

Amgen launched its Enbrel MiniTM single-dose prefilled cartridge with AutoTouchTM reusable autoinjector in the United States in 2017. The AutoTouch™ reusable autoinjector has an ergonomic design that includes features that were designed with patients in mind, including an ergonomic handle, a needle designed to stay hidden during the injection, a sensor to detect placement on skin, a speed switch with three injection speeds, a progress bar and a speaker.

Amgen turned to the patent attorneys at Marshall Gerstein for development of an extensive patent portfolio to protect this ground-breaking device. The patent strategy for the device evolved in real time along with the device. This process requires a close relationship and open line of communication between the patent attorneys, engineers, and business executives at Amgen. This unique relationship allowed Marshall Gerstein to have a deeper understanding of the technology and how it was being developed and commercialized.

The Marshall Gerstein team possesses a wealth of knowledge relating to medical devices which allowed them to more easily identify which features of a given device can and should be patented. This advantage helps save clients time and money and presents clients with opportunities they may not have seen previously.

Offsite Notice

By clicking “Proceed” below, you will be opening a new browser window and leaving our website.